ThermoGenesis Autologous TPD Receives CE Mark

ThermoGenesis announced that it has been granted the right to affix the CE mark to the Thrombin Processing Device (TPD) by the European Notified Body. The company will begin its beta launch of the TPD in June with selected hospital-based perfusionists (blood transfusion specialists) in Belgium, Holland, UK and Italy as a first step in addressing an annual world market of $180 million. A full European launch will occur by the end of this summer. The autologous TPD is a small hand-held disposable that produces 8.5 cc of activated thrombin from 11 cc of a patient's own blood plasma in roughly 25 minutes.

()a href="http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/05-26-2005/0003691729&EDATE=" target="_blank">PR Newswire